just looked back on the old posts - nice work FG - good info - helped me understand the potential issues between PXL & CST - If the PXL products gets off the ground it will go gangbusters in the non developed world - a 3 min field test for $2 would be ordered in the millions each year while CST continues to collect in the developed world. I suspect PXL would steal a $$ in the short term from CST in the developed world but your point seems right that if they can wipe out active TB then they can genuinely concentrate on latent.
If I were CST management though . . . . . with amkt cap of $200m v $40m I'd be keeping a left eye on PXL and thinking about a quick take over if the product shows promise - Might as well own the TB world.
Add to My Watchlist
What is My Watchlist?
